This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Balance Sheet Health

Financial Health criteria checks 6/6

BELLUS Health has a total shareholder equity of $368.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $379.5M and $10.6M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$312.99m
EquityUS$368.90m
Total liabilitiesUS$10.64m
Total assetsUS$379.54m

Recent financial health updates

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

May 05
We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Jan 06
Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Sep 10
Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Financial Position Analysis

Short Term Liabilities: BLU's short term assets ($327.7M) exceed its short term liabilities ($9.8M).

Long Term Liabilities: BLU's short term assets ($327.7M) exceed its long term liabilities ($834.0K).


Debt to Equity History and Analysis

Debt Level: BLU is debt free.

Reducing Debt: BLU had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BLU has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 45.4% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/28 21:22
End of Day Share Price 2023/06/28 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BELLUS Health Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Justin ZelinBTIG
Pooya HemamiEdison Investment Research